科倫藥業(002422.SZ):授權Ellipses在除大中華區及部分亞太地區外開發、銷售RET激酶抑制劑
格隆匯3月25日丨科倫藥業(002422.SZ)宣佈,公司控股子公司科倫博泰於2021年3月與英國Ellipses Pharma達成區域授權合作協議,科倫博泰將創新小分子腫瘤靶向RET激酶抑制劑項目(以下簡稱“A400項目”)歐美等區域權利有償獨家授權給Ellipses,科倫博泰保留大中華區及韓國、新加坡、馬來西亞等部分亞太地區的權利,雙方將在各自區域內進行開發、商業化等活動,並利用各自區域內數據支持項目全球研發。
A400項目是科倫博泰研發具有自主知識產權的小分子選擇性靶向RET激酶抑制劑,該項目已於2021年3月向NMPA正式提交了IND申請,並已佈局多項國際專利。臨牀前研究表明A400具有良好的體內外激酶抑制活性和選擇性;在動物血/腦暴露量等方面具有優勢;對臨牀已有報道的多種臨牀耐藥突變有效。A400具有克服臨牀耐藥突變和提高對腦轉移癌臨牀療效的潛力。
協議對方為Ellipses Pharma,是一家專注於研發創新癌症藥物和療法的國際藥物研發公司。Ellipses總部位於倫敦,由世界一流的領導團隊管理,利用世界最大的聚焦腫瘤領域的關鍵意見領袖小組的專業知識,來管理具有高質量臨牀腫瘤治療潛力的、快速增長的產品線。其遍佈全球的業務及以資產為中心的方法改變了臨牀試驗的流程,以前所未有的速度為癌症患者提供最好的藥物和療法。
公司表示,該許可協議的簽署有助於RET激酶抑制劑項目在全球的開發速度,上市後將為全球腫瘤患者提供新的治療選擇,也將進一步提升公司創新項目國際化。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.